We report the frequency of the G534a polymorphism in the Spanishamerindian population. No correlation was detected between this polymorphism and the presence of hypertension and biochemical parameters in this Chilean cohort.
The 11β-hydroxysteroid dehydrogenase type 2 enzyme (11β-HSD2) is one of the key enzymes in maintaining blood pressure (BP) homeostasis. It is encoded by the gene HSD11B2 which is located on chromosome 16q22 and consists of five exons spanning ~6.2 kb. 1 This enzyme, which converts cortisol (F) to inactive cortisone (E), is typically expressed in the adrenal gland and in tissues where the mineralocorticoid receptor is present. Impairment in 11β-HSD2 enzymatic activity results in an inefficient conversion of F to E that can trigger hypertension through the F activation of mineralocorticoid receptor. In a previous study, we found that 15.7% of essential hypertensive patients had a high F/E ratio, suggesting a defect in 11β-HSD2 activity. 2 Reduced 11β-HSD2 activity can be caused by different mechanisms such as mutations, [3] [4] [5] [6] polymorphisms in the coding region of the HSD11B2 gene, 7 epigenetic changes, 8 and by the presence of exogenous or endogenous inhibitors of 11β-HSD2 activity. 9 The frequency of mutations in the HSD11B2 gene is rare and thus alone could not account for the elevated number of essential hypertensive patients. Since 1979, when Ulick and New 10 described an autosomal recessive congenital defect that was coined apparent mineralocorticoid excess, there have been Background 11β-hydroxysteroid dehydrogenase type 2 enzyme (11β-HSD2) inactivates cortisol (F) to cortisone (E); its impairment is associated with hypertension. We reported that 15.7% of the Chilean essential hypertensives possessed a high F/E ratio suggesting a partial deficit in 11β-HSD2 activity. It has been reported that the G534a(Glu178/ Glu) polymorphism in the HSD11B2 gene is associated with hypertension. Investigate the frequency of the G534a polymorphism and its correlation with the glucocorticoid profile in Chilean essential hypertensive and normotensive subjects.
Methods
Essential hypertensive outpatients (n = 232) and normotensive subjects (n = 74) were recruited. a change in the AluI restriction enzyme digest pattern, caused by the presence of the G534a polymorphism, was utilized to screen DNa isolated from leukocytes within the cohort before confirmation by sequencing. Plasma renin activity (PRa), serum aldosterone, F, and E were measured by radioimmunoassay. Urinary tetrahydrocortisol (THF), 5α-tetrahydrocortisol (5α-THF), and tetrahydrocortisone (THE) were measured by gas chromatography-mass spectrometry.
results
G534a polymorphism frequency was similar between hypertensive patients (19 of 232; 8.2%) and normotensive subjects (7 of 74; 9.5%). When categorized by presence or absence of the G534a polymorphism, no significant differences in the serum F/E ratio or other measured biochemical variables were detected. Despite a previous report that the G534a polymorphism is associated with a neighboring C468a (Thr156/Thr) polymorphism, analysis within our cohort showed that only one patient in each group presented with this double polymorphism.
original contributions 11β-HSD2 Polymorphisms in Chilean Hypertensives 100 other cases described. 11 Two cases have been reported in the Chilean population. 3, 4 The majority of the known HSD11B2 gene mutations are found in exons 3, 4 or 5, with the exception of the R74G, P75,Δ1nt in exon 1 12 and L114,Δ6nt mutant in exon 2. 13 The clinical presentation of apparent mineralocorticoid excess in childhood includes: low birth weight, failure to thrive, short stature, severe hypertension, hypokalemia, suppressed plasma renin activity (PRA), undetectable aldosterone and an excessively high F/E ratio. 4 In recent years, the length of CA microsatellite repeats in intron 1 of the HSD11B2 gene has been associated with 11β-HSD2 enzyme activity 7 and salt sensitivity, 14 suggesting that 11β-HSD2 activity may play a crucial role in essential hypertension. In our previous study performed in Chilean hypertensive population, we demonstrated that the longer CA-alleles showed high serum F/E ratio. 7 Furthermore, polymorphisms in the HSD11B2 gene have been reported. Initially, Brand et al. described a single polymorphism G534A (Glu178/Glu) in exon 3 which did not appear to contribute to essential hypertension in a French cohort 15 and similar results were communicated in two Italian studies where no correlation was found with essential hypertension. 16, 17 However, in the Swedish population, the frequency of G534A was lower in essential hypertensive patients than in normotensive control subjects. 18 Our group recently found the presence of the G534A polymorphism in two of five essential hypertensive patients with a high F/E ratio.
Thus, the several attempts to find mutations have been fruitless and the identification of HSD11B2 gene polymorphisms that are linked to essential hypertension is controversial, suggesting that the discrepancies between studies may be dependent on the ethnic origin of the patients. 15, 16 To date, no study of polymorphisms in the HSD11B2 gene coding region has been performed outside Europe. The aim of this study was to analyze the frequency of the G534A polymorphism in the HSD11B2 gene in Chilean essential hypertensive patients and in normotensive control subjects and evaluate whether this polymorphism correlated with the glucocorticoid profile.
Methods
Subjects. We recruited 232 adult essential hypertensive patients selected from a Chilean governmental primary care center. BP records were reviewed and those patients with systolic BP >140 mm Hg and diastolic BP >90 mm Hg, on at least two occasions on separate days, were considered as hypertensive. Patients with renal disease, diabetes mellitus, hepatic failure, cardiac failure, primary aldosteronism, clinical Cushing's disease, and patients treated with glucocorticoids were excluded. In patients who were using antihypertensive drugs affecting the renin-angiotensin system such as β-blockers, angiotensinconverting enzyme inhibitors, angiotensin II receptor blockers, diuretics, and spironolactone, a washout was performed for a minimum of 15 days. The patients who were using any of these drugs were treated with doxazosin. As controls, we selected 74 adult normotensive subjects with BP <140/90 mm Hg, determined on at least two different occasions, with no history of diabetes, renal failure, hypothyroidism, exogenous glucocorticoid use or history of hypertension in first degree relatives.
Hypertensive and normotensive subjects of the present study have an ethnic origin of Spanish/white-Amerindian. Briefly, the Chilean population originated through a biracial mixture of genes originating from the Spanish conquerors and a gene pool derived from the native Amerindians. [19] [20] [21] The protocol followed in this study was written according to the guidelines of the Declaration of Helsinki and approved by the ethical committee of the Faculty of Medicine, Pontificia Universidad Católica de Chile, Santiago, Chile. The study and protocol were explained to all participants and written informed consent was obtained.
Sequencing study PCR amplification and restriction analysis of HSD11B2 gene.
Genomic DNA from peripheral leukocytes of essential hypertensive patients (n = 232) and normotensive controls (n = 74) was isolated. Intron hybridizing primers were designed to span each of the five exons. The primers were often mixed to provide overlapping sequences.
The primer sequences used and product sizes were as follows: exon 1 (sense: ACGAGAGAAAGCGAGTGTCC, antisense: ATGGGGAGTCAGTCCTGTTG, size: 477 bp); exon 2-3 (sense: CCCTGGTGATTCTGGGGTT, antisense: AGG GGGTCCTTTTTGCT, size: 621 bp); exon 3-4 (sense: GG ACTGGAAGTTTGCTGCTG, antisense: CCTGCCCCCAT AAGACCAT, size: 559 bp); exon 5 (sense: CCTGGGGCGGG TTAAACA, antisense: ATGCTGGGGGTTTTCGGGGAGG AAC, size: 574 bp). PCR products were amplified using cycling conditions that have been previously described. 7 The PCR products were isolated using the QIAquick PCR purification kit (Qiagen, Valencia, CA) according to the manufacturer's instructions.
To determine the presence of the G534A (Glu178/Glu) polymorphism in the HSD11B2 gene, the 621-bp sequence spanning exon 2 to the end of exon 3 was amplified using the primers and conditions stated above. They were digested with AluI FastDigest restriction endonuclease (Fermentas, Hanover, MD) for 30 min at 37 °C. The AluI enzyme recognizes the Genbank reported sequence AGCT and cut the 621-bp PCR product in six fragments: 282, 171, 76, 34, 32, and 26 bp (Figure 1a) . The presence of the G534A polymorphism in exon 3 changes the recognition site for the restriction endonuclease AluI from AG/CT to AA/CT preventing cleavage in one of the five restriction sites, thus generating the altered fragment size pattern: 308, 171, 76, 34, 32, and 26 bp. Only the larger fragments are shown in Figure 1b (i.e., Genbank 282 and 171, with 308 and 171 in the presence of the G534A polymorphism). Products of restriction analysis were electrophoresed on a 3% agarose gel and visualized by ethidium bromide staining. The 621-bp PCR product from all patients containing the G534A polymorphism was amplified with primers exon 2-3 sense and antisense and then sequenced in an ABIprism-377DNA genetic analyzer (Applied Biosystems, Foster City, CA (Figure 1c) ). Sequences were matched with original contributions 11β-HSD2 Polymorphisms in Chilean Hypertensives the published sequence for the HSD11B2 gene (GI:9989705) using ClustalW (Figure 1c) .
Biochemical assays. Blood and 24-h urine samples were obtained between 9:00 AM and 10:00 AM, after a 12-h fast from 173 essential hypertensive patients and 62 normotensive patients selected for the polymorphism study. The patients were seated at rest for 10 min before drawing blood samples to measure the following: sodium, potassium, PRA, aldosterone, F, and E. Previously described methods were used for these measurements. 22 In urine samples (collected without preservatives) we simultaneously measured total tetrahydrocortisol (THF), 5α-tetrahydrocortisol (5α-THF), tetrahydrocortisone (THE), cortol, β-cortol, cortolone, and β-cortolone by gas chromatography-mass spectrometry using a HewlettPackard 6890-5973Hp mass spectrometer (Hewlett-Packard, Milan, Italy) as described previously. 23 Intra-assay and interassay coefficients of variation were 7.7 and 9.4%, respectively. The sum of the F and E metabolite levels (THF, 5α-THF, THE, cortol, β-cortol, cortolone, and β-cortolone) was recorded as total THMs.
Data analysis. The results were expressed as median values (interquartile range, (Q1-Q3)). The activity of the 11β-HSD2 enzyme was assessed by measuring the serum F/E ratio. The comparison between allele frequencies was performed by the Freeman-Halton test. This test and power study was performed using statistical software R version 2.13.1. Differences between genders respect to polymorphism G534A were tested by onesided Fisher's exact test. The comparison of the biochemical variables between subject groups carrying the polymorphism G534G or G534A in HSD11B2 gene was performed using the Mann-Whitney test (GraphPad Prism, version 4.0; GraphPad Software, La Jolla, CA). Differences were considered statistically significant at P < 0.05.
results

Frequency of g534a polymorphism
Eighteen of 232 (7.8%) essential hypertensives and 6 of 74 (8.1%) normotensives possessed a heterozygous G534A polymorphism ( Table 1) . As can be observed in Figure 1b , the presence of a higher running PCR product corresponded to a homozygous G534A polymorphism (lane 2) while a double band at this position corresponded to a heterozygous individual (lane 6). To confirm the presence of this polymorphism and the state of zygosity, all exon 3 fragments suspected of possessing a change in the AluI cut pattern were reamplified and sequenced (Figure 1c) . Only one hypertensive patient and only one normotensive subject possessed homozygous A534A. The allele frequency distribution for this polymorphism was similar between the essential hypertensive patients and normotensive control subjects (P = 0.6105, two-sided P-value for Freeman-Halton test) ( Table 1) .
Biochemical study of the g534a polymorphism
The biochemical variables were analyzed in 173 essential hypertensive patients and 62 normotensive control subjects. Since only one hypertensive patient and only one normotensive subject possessed homozygous A534A, they were added to heterozygous. Subsequently, the essential hypertensives were divided into groups according to the presence or absence of the G534A polymorphism, showing similar age, body mass index, and BP (Table 2) . Furthermore, there was no significant difference in serum F, E, F/E ratio, potassium, aldosterone, and PRA values, nor in the urinary excretion of metabolites 5α-THF, THF, and THE ( Table 2) . However, an interesting observation is that the association between serum F/E ratio and PRA is extremely close to achieving significance (Spearman r = −0.4864, P = 0.066, n = 15) in hypertensive patients carrying the heterozygous G534A genotype, whereas in hypertensive patients carrying the G534G genotype, this association is far from significance (Spearman r = 0.0277, P = 0.7331, n = 154). In normotensive subjects, the comparison among individuals Values for genotype distribution are n (%).
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with or without the G534A polymorphism did not show differences in clinical characteristics or in biochemical variables (Table 3) . However, when we compared essential hypertensive with normotensive subjects possessing the same genotype, we observed differences in the excretion of the F and E tetrahydrometabolites (Figure 2) . The essential hypertensive patients containing the genotype G534A excreted more urinary 5α-THF, THE, THMs (5α-THF, THF, THE, cortol, β-cortol, cortolone and β-cortolone) and showed a tendency to excrete more THF than the normotensive controls with the same genotype. The (THF + 5α-THF)/THE ratio did not differ. A similar pattern was observed when hypertensive and normotensive subjects containing the polymorphism G534G were compared (Figure 2 ).
g534a and c468a polymorphism association
Previously published studies within an Italian population had reported a correlation of the G534A polymorphism with a neighboring polymorphism in exon 2 (C468A Thr 156/Thr). In this Italian study, the hypertensive patients presented higher frequencies of this double polymorphism. 16 To determine if this polymorphism (C468A Thr 156/Thr) was associated with the G534A polymorphism in our Chilean cohort, we sequenced the 621-bp PCR product obtained from the amplification of exons 2 and 3 from all patients already confirmed to contain the G534A polymorphism (19 hypertensive patients and 7 normotensive control subjects, Table 1 ). In this limited subgroup we observed only the homozygous A468A polymorphism, and this occurred in the presence of the homozygous A534A. Thus, after we investigated only the occurrence of both polymorphisms, we can conclude that this double change was limited to 0.4% (1 in 232) in essential hypertensive patients and 1.4% (1 in 74) in normotensive control subjects ( Table 4) .
discussion
The present study is, to the best of our knowledge, the first evaluation of the frequency of the G534A polymorphism in the HSD11B2 gene in the Latin American population. Herein, hypertensive patients and normotensive subjects were recruited from the Chilean population. Our results show there was not a significant difference in genotype frequency for the presence of this polymorphism in hypertensive patients (8.2%) and normotensive control subjects (9.5%). The frequency of the G534A polymorphism in this Chilean cohort showed remarkably similar distribution to the published French, Italian, and Swiss cohorts, [15] [16] 24 where this polymorphism was also not associated with essential hypertension ( Table 4) . In contrast, a Swedish cohort 18 showed a different distribution in respect to the other European populations analyzed. In this study, the G534A polymorphism was significantly higher in normotensive subjects than in hypertensive patients. 18 To date, only the Swedish cohort demonstrates a significant difference with regard to this polymorphism and hypertension. This discrepancy could be due to the G534A polymorphism being in linkage disequilibrium with a functional mutation affecting BP. This intriguing difference may well be Values correspond to median (Q 1 -Q 3 ). ARR, aldosterone/plasma renin activity ratio; BMI, body mass index; E, cortisone; F, cortisol; M, men; n, number of subjects; ns, not significant; PRA, plasma renin activity; SA, serum aldosterone; THE, tetrahydrocortisone; THF, tetrahydrocortisol, 5α-THF, 5α-tetrahydrocortisol; W, women. Values correspond to median (Q 1 -Q 3 ). ARR, aldosterone/plasma renin activity ratio; BMI, body mass index; E, cortisone; F, cortisol; M, men; n, number of subjects; ns, not significant; PRA, plasma renin activity; SA, serum aldosterone; THE, tetrahydrocortisone; THF, tetrahydrocortisol, 5α-THF, 5α-tetrahydrocortisol; W, women.
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isolated to the Swedish population and awaits confirmation in other Scandinavian cohorts. As previously mentioned, our Chilean cohort is of predominantly Spanish descent, but unfortunately there are limited data available from the current Spanish population to make any comparisons on the frequency of this polymorphism. The only study performed in a Spanish cohort from Barcelona, which recruited only hypertensive patients, observed that subjects with the G534G genotype possessed a significantly higher systolic BP increase upon high salt intake than that observed in patients carrying the G534A polymorphism. 25 The absence of normotensive subjects within this Spanish study prevents comparison with our Chilean study. It would be valuable to rigorously examine both populations in a future study with a larger number of subjects to improve the statistical power. Despite observing no differences in the G534A polymorphism frequency in our Chilean cohort of hypertensives and normotensives, we were curious to ascertain if the presence of this polymorphism correlated with the F/E ratio, F metabolite metabolism or other biochemical parameters. Herein, we found that the serum F/E ratio (an index of 11β-HSD2 enzyme activity) and the excretion of their urinary metabolites did not differ among subjects who presented with a G534G or G534A genotype. In contrast, the subjects carrying the G534G 
Figure 2 | Urinary excretion of cortisol metabolites in essential hypertensive patients and normotensive subjects with and without the G534a (Glu178/Glu) polymorphism. NT, normotensive; THE, tetrahydrocortisone; THF, tetrahydrocortisol; 5α-THF, 5α-tetrahydrocortisol; THMs, 5α-THF+THF+THE+cortols+cortolones. Gray boxes represent hypertensive and normotensive subjects with the G534a polymorphism.
original contributions 11β-HSD2 Polymorphisms in Chilean Hypertensives polymorphism in the Swedish study had significantly higher urinary F to E metabolite ratios compared to carriers of the G534A and A534A genotype. 18 However, the Chilean essential hypertensive patients showed significantly higher 5α-THF and THE excretion and a tendency for higher THF excretion than the normotensive subjects in both genotypes (Figure 2) , suggesting that hypertensive patients synthesize and metabolize more F than normotensive subjects irrespective of the G543A polymorphism.
In addition, Chilean hypertensive and normotensive subjects possessing the G534A and the G534G polymorphisms showed similar serum aldosterone, PRA, and aldosterone/ renin ratio. However, a notable observation is the association between serum F/E ratio and PRA, which is extremely close to achieving significance in hypertensive patients carrying the G534A genotype, suggesting that this may be a possible mechanism to trigger hypertension, whereas in hypertensive patients carrying the G534G genotype, there is no such obvious tendency. Interestingly, in the above-mentioned Spanish study, the suppression of PRA in response to high salt intake was significantly greater in patients carrying the G534A polymorphism. 25 Another noteworthy observation was the report from an Italian cohort study finding an association between the G534A polymorphism and a neighboring polymorphism, C468A (Thr156/Thr), in exon 2. This double polymorphism was reported to be significantly higher in hypertensive patients compared to control subjects (Table 4) . Unfortunately, the presence of the C468A genotype in exon 2 was not investigated in French, Swedish, Swiss, or Spanish studies. 15, 18, 24, 25 In our Chilean study, which examined only the double polymorphism and not the C468A frequency alone, we found an extremely low frequency of this double polymorphism and no significant difference between the hypertensive and normotensive groups. However, although the numbers are too low for statistical analysis (one hypertensive patient and one normotensive subject), it is remarkable to the authors that this exon 2 polymorphism only presented in the presence of the homozygous exon 3 polymorphism in both the hypertensive patient and the normotensive subject. Furthermore, this exon 2 polymorphism was also homozygous in both groups. This observation may warrant further investigation; however, given that the double polymorphism occurred at a frequency of only 1% in our Chilean cohort, a future study would require a much larger number of patients.
In summary, we report the frequency of the G534A polymorphism in a Spanish-Amerindian population. Our observations do not demonstrate a mutation in the HSD11B2 gene or a correlation between the G534A polymorphism and essential hypertension; however, we cannot rule out that epigenetic modifications to the regulation of this enzyme may play an important role in the etiology of this pathology. Our results do show differences in polymorphism frequency and biochemical analysis compared with European cohorts and thus warrant further studies to fully understand polymorphism significance and population differences in 11β-HSD2 activity. 
